{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:25:06Z","timestamp":1793413506959,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.anai.2024.12.003","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:20:06Z","timestamp":1734049206000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A second look at secondary hypogammaglobulinemia"],"prefix":"10.1016","volume":"134","author":[{"given":"Rose","family":"Monahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris M.","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather K.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Shahzad","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2024.12.003_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1380654","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients","volume":"15","author":"Elgenidy","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.anai.2024.12.003_bib0002","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0003","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12969-019-0365-y","article-title":"Rituximab-associated hypogammaglobulinemia in pediatric patients with autoimmune diseases","volume":"17","author":"Khojah","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0005","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1542\/peds.2008-2361","article-title":"B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus","volume":"123","author":"Kumar","year":"2009","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.anai.2024.12.003_bib0006","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s00467-023-05913-1","article-title":"Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey","volume":"38","author":"Zurowska","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0007","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"issue":"7","key":"10.1016\/j.anai.2024.12.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.anai.2024.12.003_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaip.2019.07.032","article-title":"Rituximab unveils hypogammaglobulinemia and immunodeficiency in children with autoimmune cytopenia","volume":"8","author":"Ottaviano","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.anai.2024.12.003_bib0012","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the gallium study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0013","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.anai.2024.12.003_bib0014","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.anai.2024.12.003_bib0015","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/rheumatology\/ker106a","article-title":"BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis","volume":"50","author":"Bukhari","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.anai.2024.12.003_bib0016","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0017","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.anai.2024.12.003_bib0018","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0019","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0020","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.anai.2024.12.003_bib0021","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0022","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.anai.2024.12.003_bib0023","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0024","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.anai.2024.12.003_bib0026","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.anai.2024.12.003_bib0027","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0028","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.anai.2024.12.003_bib0029","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.anai.2023.01.010","article-title":"Steroid-induced secondary immune deficiency","volume":"130","author":"Mustafa","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.12.003_bib0031","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s10875-016-0264-7","article-title":"Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency","volume":"36","author":"Wirsum","year":"2016","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0032","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000064258","article-title":"Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone","volume":"128","author":"Kawano","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0033","first-page":"472","article-title":"Hypogammaglobulinemia in asthmatic patients","volume":"68","author":"Hamilos","year":"1992","journal-title":"Ann Allergy"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0034","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0091-6749(78)90101-X","article-title":"Corticosteroid effect on immunoglobulins","volume":"62","author":"Settipane","year":"1978","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0035","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0022-3476(96)70035-5","article-title":"Humoral immunity in steroid-dependent children with asthma and hypogammaglobulinemia","volume":"129","author":"Lack","year":"1996","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.anai.2024.12.003_bib0036","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.anai.2024.12.003_bib0037","first-page":"1473","article-title":"Immune status and risk for infection in patients receiving chronic immunosuppressive therapy","volume":"32","author":"Gl\u00fcck","year":"2005","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0038","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/PL00021707","article-title":"Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy","volume":"15","author":"Ogawa","year":"2005","journal-title":"Mod Rheumatol"},{"issue":"8","key":"10.1016\/j.anai.2024.12.003_bib0039","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/339548","article-title":"Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome","volume":"34","author":"Sepkowitz","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0040","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.jaip.2023.04.018","article-title":"Inborn errors of immunity and autoimmune disease","volume":"11","author":"Gray","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0041","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/annrheumdis-2020-218280","article-title":"High frequency of variants in genes associated with primary immunodeficiencies in patients with rheumatic diseases with secondary hypogammaglobulinaemia","volume":"80","author":"Sogkas","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0042","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/MOP.0000000000001396","article-title":"Secondary hypogammaglobulinemia: diagnosis and management of a pediatric condition of clinical importance","volume":"36","author":"DiGiacomo","year":"2024","journal-title":"Curr Opin Pediatr"},{"issue":"11","key":"10.1016\/j.anai.2024.12.003_bib0043","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1177\/1352458513477229","article-title":"Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients","volume":"19","author":"Selter","year":"2013","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.anai.2024.12.003_bib0044","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1191\/1352458503ms926oa","article-title":"Safety and tolerability of cyclophosphamide \u201cpulses\u201d in multiple sclerosis: a prospective study in a clinical cohort","volume":"9","author":"Portaccio","year":"2003","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ACI.0000000000000485","article-title":"Secondary antibody deficiency in neurology","volume":"18","author":"Tallantyre","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0046","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.seizure.2011.12.013","article-title":"Carbamazepine-induced hypogammaglobulinemia","volume":"21","author":"Ozaras","year":"2012","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0047","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1365-2249.2003.02097.x","article-title":"Immunoglobulins in children with epilepsy: the Dutch Study of epilepsy in Childhood","volume":"132","author":"Callenbach","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0048","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10072-012-1153-3","article-title":"Valproate-induced panhypogammaglobulinemia","volume":"34","author":"Eom","year":"2013","journal-title":"Neurol Sci"},{"issue":"10","key":"10.1016\/j.anai.2024.12.003_bib0049","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/00365540260348662","article-title":"Reversible panhypogammaglobulinemia associated with phenytoin treatment","volume":"34","author":"Pereira","year":"2002","journal-title":"Scand J Infect Dis"},{"issue":"7","key":"10.1016\/j.anai.2024.12.003_bib0050","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.anai.2024.12.003_bib0051","unstructured":"U.S. Food and Drug Administration. VYVGARTTM (efgartigimod alfa-fcab) [package insert]. Accessed October 6, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761195s000lbl.pdf"},{"key":"10.1016\/j.anai.2024.12.003_bib0052","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0053","doi-asserted-by":"crossref","first-page":"85","DOI":"10.15586\/aei.v52i1.961","article-title":"Neurological involvement in patients with primary immunodeficiency","volume":"52","author":"Kose","year":"2024","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.anai.2024.12.003_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104086","article-title":"Common variable immunodeficiency and its inflammatory neurological manifestations: a case report and literature review","volume":"67","author":"Martins","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1016\/j.anai.2024.12.003_bib0055","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s10875-020-00861-z","article-title":"Neurologic conditions and symptoms reported among common variable immunodeficiency patients in the USIDNET","volume":"40","author":"Lee","year":"2020","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0056","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1378\/chest.118.3.712","article-title":"Peripheral blood CD4 + T-lymphocyte counts during pneumocystis carinii pneumonia in immunocompromised patients without HIV infection","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172437","article-title":"Antibody deficiency in patients with frequent exacerbations of chronic obstructive pulmonary disease (COPD)","volume":"12","author":"McCullagh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.anai.2024.12.003_bib0058","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2147\/COPD.S236656","article-title":"Hypogammaglobulinemia and risk of exacerbation and mortality in patients with COPD","volume":"15","author":"Holm","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.anai.2024.12.003_bib0059","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.chest.2020.04.058","article-title":"Serum IgG levels and risk of COPD hospitalization: a pooled meta-analysis","volume":"158","author":"Leitao Filho","year":"2020","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12931-018-0923-8","article-title":"Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management","volume":"19","author":"Soler-Palac\u00edn","year":"2018","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0061","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10875-019-00738-w","article-title":"Pulmonary disease burden in primary immune deficiency disorders: data from USIDNET registry","volume":"40","author":"Patrawala","year":"2020","journal-title":"J Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2024.12.003_bib0062","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1007\/s10875-023-01593-6","article-title":"Respiratory comorbidities associated with bronchiectasis in patients with common variable immunodeficiency in the USIDNET registry","volume":"43","author":"Correa-Jimenez","year":"2023","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0063","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"issue":"suppl 1","key":"10.1016\/j.anai.2024.12.003_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British Thoracic Society Guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.anai.2024.12.003_bib0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198001313020501","article-title":"Hypogammaglobulinemia in patients with cystic fibrosis","volume":"302","author":"Matthews","year":"1980","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2024.12.003_bib0066","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0022-3476(84)80946-4","article-title":"Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study","volume":"104","author":"Wheeler","year":"1984","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.anai.2024.12.003_bib0067","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.medcli.2023.10.005","article-title":"Secondary hypogammaglobulinemia in adults\u2014a large retrospective cohort study","volume":"162","author":"Angarola","year":"2024","journal-title":"Med Clin"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0068","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10875-022-01368-5","article-title":"Lymphoma as an exclusion criteria for CVID diagnosis revisited","volume":"43","author":"Allain","year":"2023","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0069","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jaci.2017.05.024","article-title":"Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry","volume":"141","author":"Mayor","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ajh.21903","article-title":"Malignancies in the setting of primary immunodeficiency: implications for hematologists\/oncologists","volume":"86","author":"Shapiro","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.anai.2024.12.003_bib0071","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.12.003_bib0072","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.12067","article-title":"Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia","volume":"159","author":"Oscier","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0073","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin?","volume":"34","author":"Dhalla","year":"2014","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0074","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0075","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ACI.0000000000000215","article-title":"Secondary antibody deficiencies","volume":"15","author":"Dhalla","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"suppl 1","key":"10.1016\/j.anai.2024.12.003_bib0076","first-page":"21","article-title":"The use of intravenous immune globulin in multiple myeloma","volume":"97","author":"Chapel","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.anai.2024.12.003_bib0077","unstructured":"National Comprehensive Cancer Network. Pediatric Acute Lymphoblastic Leukemia. version 1.2025. Accessed October 6, 2024. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ped_all.pdf"},{"issue":"8","key":"10.1016\/j.anai.2024.12.003_bib0078","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/bmt.2009.254","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective","volume":"44","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.anai.2024.12.003_bib0079","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0080","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bmt.2014.28","article-title":"Risk factors for hypogammaglobulinemia after allo-SCT","volume":"49","author":"Arai","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.anai.2024.12.003_bib0081","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/bmt.2013.76","article-title":"Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT","volume":"48","author":"Frangoul","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0082","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.bmt.1705870","article-title":"Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality","volume":"41","author":"Berger","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0083","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1399-3062.2008.00329.x","article-title":"Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection","volume":"10","author":"Carbone","year":"2008","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"10.1016\/j.anai.2024.12.003_bib0084","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis","volume":"13","author":"Florescu","year":"2013","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.anai.2024.12.003_bib0085","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/01.tp.0000180531.66518.9e","article-title":"Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes","volume":"81","author":"Doron","year":"2006","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0086","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00007890-200101270-00013","article-title":"Hypogammaglobulinemia in lung transplant recipients","volume":"71","author":"Goldfarb","year":"2001","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.anai.2024.12.003_bib0087","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/01.TP.0000159136.72693.35","article-title":"Risk factors and outcomes of hypogammaglobulinemia after lung transplantation","volume":"79","author":"Kawut","year":"2005","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0088","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/ejcts\/ezt583","article-title":"Effect of hypogammaglobulinemia after lung transplantation: a single-institution study","volume":"45","author":"Ohsumi","year":"2014","journal-title":"Eur J Cardio Thorac Surg"},{"issue":"8","key":"10.1016\/j.anai.2024.12.003_bib0089","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1097\/TXD.0000000000000811","article-title":"A prospective observational study of hypogammaglobulinemia in the first year after lung transplantation","volume":"4","author":"Petrov","year":"2018","journal-title":"Transplant Direct"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0090","doi-asserted-by":"crossref","first-page":"e12628","DOI":"10.1111\/tid.12628","article-title":"Post-transplant hypogammaglobulinemia and risk of infection after kidney transplantation: magnitude matters","volume":"19","author":"Fern\u00e1ndez-Ruiz","year":"2017","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"10.1016\/j.anai.2024.12.003_bib0091","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s15010-015-0737-2","article-title":"Potential role of post-transplant hypogammaglobulinemia in the risk of Clostridium difficile infection after kidney transplantation: a case-control study","volume":"43","author":"Orig\u00fcen","year":"2015","journal-title":"Infection"},{"issue":"8","key":"10.1016\/j.anai.2024.12.003_bib0092","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.200510-1609OC","article-title":"Immunoglobulin G levels before and after lung transplantation","volume":"173","author":"Yip","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2024.12.003_bib0093","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1399-3062.2003.00035.x","article-title":"Immunoglobulin deficiency in kidney allograft recipients: comparative effects of mycophenolate mofetil and azathioprine","volume":"5","author":"Keven","year":"2003","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0094","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.iac.2018.08.005","article-title":"Secondary hypogammaglobulinemia: an increasingly recognized complication of treatment with immunomodulators and after solid organ transplantation","volume":"39","author":"Kaplan","year":"2019","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"10.1016\/j.anai.2024.12.003_bib0095","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00467-021-05345-9","article-title":"Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome","volume":"37","author":"Chan","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0096","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0272-6386(12)80899-7","article-title":"Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome","volume":"24","author":"Ogi","year":"1994","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0097","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00467-022-05652-9","article-title":"The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome","volume":"38","author":"Inoki","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.anai.2024.12.003_bib0098","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2215\/CJN.08570722","article-title":"Use of rituximab in childhood idiopathic nephrotic syndrome","volume":"18","author":"Chan","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0099","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ajg.2009.561","article-title":"Protein-losing enteropathy: case illustrations and clinical review","volume":"105","author":"Umar","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.anai.2024.12.003_bib0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005581","article-title":"A hereditary enteropathy caused by mutations in the SLCO2A1 gene, encoding a prostaglandin transporter","volume":"11","author":"Umeno","year":"2015","journal-title":"PLoS Genet"},{"issue":"7","key":"10.1016\/j.anai.2024.12.003_bib0101","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s10875-022-01299-1","article-title":"Protein-losing Enteropathy as a Complication and\/or Differential Diagnosis of common variable immunodeficiency","volume":"42","author":"Sanges","year":"2022","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0102","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaip.2015.11.034","article-title":"Risk factors and clinical significance of lymphopenia in survivors of the Fontan procedure for single-ventricle congenital cardiac disease","volume":"4","author":"Morsheimer","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"18","key":"10.1016\/j.anai.2024.12.003_bib0103","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.12998\/wjcc.v12.i18.3298","article-title":"Intestinal lymphangiectasia: understanding the bigger picture","volume":"12","author":"Marrapu","year":"2024","journal-title":"World J Clin Cases"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0104","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1056\/NEJMoa1615887","article-title":"CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis","volume":"377","author":"Ozen","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.anai.2024.12.003_bib0105","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ejhg.2016.5","article-title":"Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations","volume":"24","author":"Stephen","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0106","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.anai.2024.12.003_bib0107","unstructured":"Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). Vaccine recommendations and guidelines. Accessed October 7, 2024. Available at: https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/immunocompetence.html"},{"issue":"23","key":"10.1016\/j.anai.2024.12.003_bib0108","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0109","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.anai.2024.12.003_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108897","article-title":"Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: effect of timing and immunologic parameters","volume":"234","author":"Magliulo","year":"2022","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0111","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","article-title":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study","volume":"48","author":"Boleto","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0112","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.anai.2024.12.003_bib0113","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1016\/j.clml.2020.04.006","article-title":"The use of 20% subcutaneous immunoglobulin replacement therapy in patients with B cell non-Hodgkin lymphoma with humoral immune dysfunction after treatment with rituximab","volume":"20","author":"Mustafa","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.anai.2024.12.003_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102851","article-title":"Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment","volume":"50","author":"Smets","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0115","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41375-021-01500-1","article-title":"SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia","volume":"36","author":"Mellinghoff","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0116","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.anai.2024.12.003_bib0117","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.anai.2024.12.003_bib0118","doi-asserted-by":"crossref","first-page":"1195.e1","DOI":"10.1016\/j.jtct.2024.09.011","article-title":"Antibiotic prophylaxis during allogeneic stem cell transplantation-a comprehensive Single Center retrospective analysis","volume":"30","author":"Neuerburg","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0119","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s10875-017-0469-4","article-title":"Prescribing immunoglobulin replacement therapy for patients with non-classical and secondary antibody deficiency: an analysis of the practice of clinical immunologists in the UK and Republic of Ireland","volume":"38","author":"Edgar","year":"2018","journal-title":"J Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2024.12.003_bib0120","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/00325481.2017.1362938","article-title":"Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review","volume":"129","author":"Cornett","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.anai.2024.12.003_bib144","unstructured":"European Medicines Agency. Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg). 2018. Accessed October 20, 2024. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-rev-4_en.pdf."},{"issue":"8","key":"10.1016\/j.anai.2024.12.003_bib145","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.anai.2024.12.003_bib146","unstructured":"Australian National Blood Authority (2023). Secondary hypogammaglobulinemia unrelated to hematological malignancy or HSCT. Accessed October 20, 2024. Available at https:\/\/www.criteria.blood.gov.au\/MedicalCondition\/View\/2687."},{"key":"10.1016\/j.anai.2024.12.003_bib147","unstructured":"Australian National Blood Authority (2020). Acquired hypogammaglobulinemia secondary to hematological malignancies or post-hematopoietic stem cell transplant. Accessed October 20, 2024. Available at https:\/\/www.criteria.blood.gov.au\/MedicalCondition\/View\/2621."},{"issue":"25","key":"10.1016\/j.anai.2024.12.003_bib148","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.anai.2024.12.003_bib0136","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/bjh.18075","article-title":"Guideline for the treatment of chronic lymphocytic leukaemia","volume":"197","author":"Walewska","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anai.2024.12.003_bib0128","unstructured":"National Comprehensive Cancer Network. Chronic lymphocytic leukemia\/small lymphocytic lymphoma. Version 1.2025. Accessed October 20, 2024. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf"},{"issue":"10","key":"10.1016\/j.anai.2024.12.003_bib0123","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.anai.2024.12.003_bib149","unstructured":"National Comprehensive Cancer Network. Hematopoietic Cell Transplantation (HCT). NCCN.Version 2.2024 \u2014 August 30, 2024; Accessed October 20, 2024. Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hct.pdf."},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0124","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anai.2024.12.003_bib0121","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bmb\/ldn034","article-title":"The immunodeficiency of chronic lymphocytic leukaemia","volume":"87","author":"Hamblin","year":"2008","journal-title":"Br Med Bull"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0122","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2257.1995.tb00322.x","article-title":"Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia","volume":"17","author":"Boughton","year":"1995","journal-title":"Clin Lab Haematol"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0125","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"issue":"3S","key":"10.1016\/j.anai.2024.12.003_bib0126","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0127","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0129","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years","volume":"125","author":"Lucas","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0130","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ajco.13515","article-title":"Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy","volume":"17","author":"Windegger","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"issue":"7","key":"10.1016\/j.anai.2024.12.003_bib0131","doi-asserted-by":"crossref","first-page":"e13625","DOI":"10.1111\/ctr.13625","article-title":"Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: a systematic review and meta-analysis - part II: non-kidney transplant","volume":"33","author":"Bourassa-Blanchette","year":"2019","journal-title":"Clin Transpl"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0132","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2015-05-647552","article-title":"Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy","volume":"127","author":"Ammann","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.anai.2024.12.003_bib0133","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients","volume":"99","author":"Compagno","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.anai.2024.12.003_bib0134","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.intimp.2013.02.021","article-title":"Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients","volume":"15","author":"Shankar","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.anai.2024.12.003_bib0135","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0137","first-page":"96","article-title":"Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia","volume":"18","author":"Windegger","year":"2020","journal-title":"Blood Transfus"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0138","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10198-004-0250-5","article-title":"Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance","volume":"6","author":"H\u00f6gy","year":"2005","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.anai.2024.12.003_bib0139","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2249.2009.04079.x","article-title":"Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies","volume":"160","author":"Beaut\u00e9","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.12.003_bib0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-3148.2012.01201.x","article-title":"Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency","volume":"23","author":"Martin","year":"2013","journal-title":"Transfus Med"},{"issue":"3","key":"10.1016\/j.anai.2024.12.003_bib0141","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/vox.12760","article-title":"Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency","volume":"114","author":"Windegger","year":"2019","journal-title":"Vox Sang"},{"key":"10.1016\/j.anai.2024.12.003_bib0142","unstructured":"U.S. Food and Drug Administration. Gammagard S\/D [package insert]. Accessed October 4, 2024. Available at: https:\/\/www.fda.gov\/media\/78185\/download"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624017265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624017265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T09:25:05Z","timestamp":1740993905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120624017265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":148,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1081120624017265"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.12.003","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A second look at secondary hypogammaglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}